Key result
The Magmaris fully bioresorbable scaffold is discussed as a transient coronary device providing mechanical support for three to six months to prevent acute recoil and constrictive remodeling.
Discusses the concept of bioresorbable scaffolds and questions whether recent data on the Magmaris magnesium scaffold justifies a return to BRS research and randomized controlled trials.
Concept and design of a bioresorbable scaffold, which “does its job and disappears” A fully bioresorbable scaffold (BRS) should be viewed as a transient coronary implantation device which prevents acute recoil and constrictive remodelling for a limited duration of time, elutes an antiproliferative drug to avoid excessive neointimal hyperplasia and then disappears by biodegradation (“does its job and disappears”)1. Since the peak of chronic vascular constriction and neointima hyperplasia occurs approximately three to six months after balloon angioplasty and/or bare metal stenting2,3,4, a BRS providing mechanical support for three to six months with ...
No takes yet. Share an insight, caveat, or question.
Onuma et al. (2020) conducted an editorial in Coronary artery disease. Magmaris bioresorbable scaffold was evaluated. The Magmaris fully bioresorbable scaffold is discussed as a transient coronary device providing mechanical support for three to six months to prevent acute recoil and constrictive remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: